Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,138 total articles

UnitedHealth Leads Gains as GE and Tractor Supply Slip; Broad Swings Across Market Caps

UnitedHealth Leads Gains as GE and Tractor Supply Slip; Broad Swings Across Market Caps

Tuesday's session produced sizable moves across the market-cap spectrum, with UnitedHealth Group surging nearly 9% among mega-caps and Northern Trust posting a notable gain in the large-cap cohort. Several established names, including General Electric and Tractor Supply Company, registered double-digit declines. The day featured both corporate-spec…

Alaska Air Pulls Annual Guidance as Jet Fuel Costs Spike

Alaska Air Pulls Annual Guidance as Jet Fuel Costs Spike

Alaska Air Group has suspended its full-year guidance after volatile jet fuel prices and sharply higher refining margins squeezed the carrier's ability to plan for the remainder of the year. The airline is recouping roughly one-third of the recent fuel cost increase through fare hikes, but the remaining gap is expected to weigh on June-quarter resu…

Microsoft trims Game Pass fees, removes Call of Duty day-one access

Microsoft trims Game Pass fees, removes Call of Duty day-one access

Microsoft announced lower monthly prices for Xbox Game Pass Ultimate and PC Game Pass and said upcoming Call of Duty titles will no longer be available on day one through the subscription service. The move - the first significant strategic change under gaming chief Asha Sharma - rolls back an earlier decision made after Microsoft acquired Activisio…

What to Know About Psychedelic Therapies Cited by Trump

What to Know About Psychedelic Therapies Cited by Trump

A recent executive order from President Donald Trump directs health regulators to accelerate reviews of psychedelic treatments and expand federal funding for related research, prompted in part by advocates for ibogaine. Most psychedelics remain Schedule I substances in the United States, yet several compounds - including psilocybin, MDMA, ibogaine …